Diffuse Aggressive Histologies of Non-Hodgkin Lymphoma: Treatment and Biology of Limited Disease

Seminars in Hematology

Volumn 43, Issue 4, 2006, Pages 207-212

  Miller, Thomas P ^a   Spier, Catherine M ^a   Rimsza, Lisa ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; METASTASIS; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TISSUE SECTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, DIFFUSE; NEOPLASM STAGING; PREDNISONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; VINCRISTINE;

EID: 33749262192     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.07.001     Document Type: Article

References (29)

1. Miller T.P., and Jones S.E. Chemotherapy of localized histiocytic lymphoma. Lancet 8 (1979) 358-360
2. Hehn S.T., Grogan T.M., and Miller T.P. Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 22 (2004) 3046-3052
3. Spier C.M., LeBlanc M., Chase E.M., Fisher R.I., and Miller T.P. Histologic subtypes do not confer unique outcomes in early-stage lymphoma: Long-term followup of SWOG 8736. Blood 104 (2004) 891a (abstr)
4. Miller T.P., Dahlberg S., Cassady J.R., Adelstein D.J., Spier C.M., and Grogan T.M. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1989) 21-26
5. Shenkier T.N., Voss N., Fairey R., Gascoyne R.D., Hoskins P., Klimo P., et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: An 18 year experience from the British Columbia Cancer Agency. J Clin Oncol 20 (2002) 197-204
6. Friedberg J.W., and Chengazi V. PET scans in the staging of lymphoma: Current status. Oncologist 8 (2003) 438-447
7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
8. Miller T.P., LeBlanc M., Spier C.M., Chase E.M., and Fisher R.I. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphoma: Update of the Southwest Oncology Group (SWOG) randomized trial. Blood 98 (2001) 724a
9. Miller T.P., Unger J.M., Spier C., Stea B., Cantu E., LeBlanc M., and Fisher R.I. Effect of adding rituximab to three cycles of CHOP, plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood 104 (2004) 48a (abstr)
10. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346 (2002) 235-242
11. Sehn L.H., Donaldson J., Chhanabhai M., Fitzgerald C., Gill K., Klasa R., et al. Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. Blood 102 (2003) 29 (abstr)
12. Reyes F., Lepage E., Ganem G., Molina T.J., Brice P., Coiffier B., et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352 (2005) 1197-1205
13. Fillet G., Bonnet C., Mounier N., Ganem G., Molina T., Thieblement C., et al. No role for chemoradiotherapy when compared with chemotherapy alone in elderly patients with localized low risk aggressive lymphoma: Final results of the LNH93-4 GELA study. Blood 106 (2005) 9a (abstr)
14. Horning S.J., Weller E., Kim K., Earle J.D., O'Connell M.J., Habermann T.M., et al. Chemotherapy with or without radiotherapy in limited stage diffuse aggressive non-Hodgkin lymphoma. J Clin Oncol 22 (2004) 3032-3038
15. Riemersma S.A., Jordanova E.S., Schop R.F., Phillipo K., Looujenga L.H., Schuuring E., et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 96 (2000) 3569-3577
16. Jordanova E.S., Riemersma S.A., Philippo K., Giphart-Gassler M., Schuuring E., and Kluin P.M. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 35 (2001) 38-48
17. Jordanova E.S., Philippo K., Giphart M.J., Schuuring E., and Kluin P.M. Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics 55 (2003) 203-209
18. Zucca E., Conconi A., Mughal T.I., Sarris A.H., Seymour J.F., Vitolo U., et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21 (2003) 20-27
19. List A.F., Spier C.M., Miller T.P., and Grogan T.M. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: Relationship to HLA expression and host immunocompetence. Leukemia 7 (1993) 398-403
20. Rimsza L.M., Roberts R.A., Campo E., Grogan T.M., Bea S., Salaverria I., et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: A follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 103 (2004) 4251-4258
21. Stopeck A.T., Gessner A., Miller T.P., Hersh E.M., Johnson C.S., Cui H., et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 6 (2000) 3904-3909
22. Jacob M.C., Piccinni M.P., Bonnefoix T., Sotto M.F., Couderc P., Bensa J.C., et al. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma: Reactivity toward the malignant clone. Blood 75 (1990) 1154-1162
23. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
24. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
25. Hoefnagel J.J., Dijkman R., Basso K., Jansen P.M., Hallermann C., Willemze R., et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105 (2005) 3671-3678
26. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
27. Jaffe E.S. WHO Classification of Tumours, Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues (2001), IARC, Lyon, France
28. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 198 (2003) 851-862
29. Savage K.J., Monti S., Kutok J.L., Cattoretti G., Neuberg D., De Leval L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102 (2003) 3871-3879